Surgical Treatment of Neuroblastoma.
Isr Med Assoc J
; 19(11): 691-695, 2017 Nov.
Article
en En
| MEDLINE
| ID: mdl-29185283
BACKGROUND: Neuroblastoma is the most common non-central nervous system (CNS) solid malignant tumor in children. The surgical treatment of high-risk neuroblastoma presents a challenge, and the benefits of aggressive surgical resection have been called into question. OBJECTIVES: To examine our experience with surgical resection of neuroblastoma. METHODS: We report on a retrospective chart review of our preliminary surgical experience in 25 patients with neuroblastoma who underwent surgery performed by a single surgeon at two institutions over a 3 year period. Demographic data, including stage of tumor and risk stratification, were recorded. Primary outcome was total gross resection. Patients were followed for 3 years after surgery. RESULTS: We found that 80% of the patients, including those with high-risk neuroblastoma tumors, had total gross resection of their tumor with minimal operative morbidity and no mortality; 88% had greater than 90% resection of their tumor. Overall, 3 year survival was 84% (21/25). CONCLUSIONS: Resection of neuroblastoma, even large, high-risk, bilateral tumors, was possible when performed by surgical teams with considerable experience.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias del Sistema Nervioso Periférico
/
Complicaciones Posoperatorias
/
Procedimientos Quirúrgicos Operativos
/
Medición de Riesgo
/
Neuroblastoma
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Prognostic_studies
Límite:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
País/Región como asunto:
Asia
Idioma:
En
Revista:
Isr Med Assoc J
Asunto de la revista:
MEDICINA
Año:
2017
Tipo del documento:
Article
País de afiliación:
Israel